Source / Disclosures
Disclosures: Drysdale is employed by Cybin. Johnson is employed by Kernel.
Neurotechnology firm Kernel and biopharmaceutical company Cybin announce promising pilot results from a feasibility study of Kernel Flow, a technology that measures states of brain activity in consciousness of altered states.
Preliminary data from the Cybin-sponsored study suggested that functional connectivity in ketamine-induced changes continued for several days after administration, with headset technology effectively measuring the drug’s neuro-effects over 11 days.
“By utilizing [Kernel] Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics, ” Doug Drysdale, Cybin CEO, said in a release statement. “Measuring where and how psychedelics work in the brain unlocks new frontiers in the discovery of this space.”
Participants in the pilot study received either a low dose of ketamine or a placebo while wearing the flow headset, which confirmed changes in functional connectivity consistent with current scientific research.
“The quality of the data recorded with the flow may lead to a better understanding of the neuro effects on psychedelics from the brain and to help advance these powerful new therapies for patients,” Bryan Johnson, Kernel CEO, said in the release.
Enrollment for the feasibility study, which began in March, is ongoing.